Clinical investigation: Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab
書誌事項
- タイトル別名
-
- Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.
この論文をさがす
抄録
PURPOSE: To evaluate the efficacy of intravitreal bevacizumab (IVB) in eyes with polypoidal choroidal vasculopathy (PCV). METHODS: Seventeen eyes of 16 patients with either subfoveal or juxtafoveal PCV were treated with IVB. As the initial treatment, ten eyes were treated with a single injection of bevacizumab and seven were treated with three monthly injections. Additional IVB injections were performed in 15 eyes when either a recurrent or residual exudative change was seen. Follow-up after initiation of IVB ranged from 12 to 30 months (mean, 20.7 +/- 5.7 months). RESULTS: The mean foveal thickness before IVB (492 +/- 205 microm) decreased to 384 +/- 181 microm at 3 months (P = 0.0008), and with additional IVB for recurrent exudative changes, the foveal thickness remained significantly reduced at 12 months (392 +/- 203 microm, P = 0.0270). Mean visual acuity at baseline (0.54 +/- 0.38 in logMAR) somewhat improved to 0.45 +/- 0.32 at 3 months (P = 0.156). However, the improvement in visual acuity then subsided, and returned to the pretreatment value at 12 months (0.54 +/- 0.39). CONCLUSIONS: In eyes with PCV, IVB can reduce the exudative change and can maintain visual function for at least 1 year.
収録刊行物
-
- Japanese journal of ophthalmology
-
Japanese journal of ophthalmology 54 (4), 310-319, 2010-07
Springer
- Tweet
キーワード
- age-related macular degeneration
- bevacizumab
- polypoidal choroidal vasculopathy
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors/administration & dosage
- Antibodies, Monoclonal/administration & dosage
- Choroid/blood supply
- Choroid Diseases/diagnosis
- Choroid Diseases/drug therapy
- Choroid Diseases/physiopathology
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Injections
- Male
- Middle Aged
- Peripheral Vascular Diseases/diagnosis
- Peripheral Vascular Diseases/drug therapy
- Peripheral Vascular Diseases/physiopathology
- Retreatment
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A/antagonists & inhibitors
- Visual Acuity/physiology
- Vitreous Body
詳細情報 詳細情報について
-
- CRID
- 1050282677154823424
-
- NII論文ID
- 10027204523
-
- NII書誌ID
- AA00691177
-
- ISSN
- 00215155
- 16132246
-
- HANDLE
- 2433/130712
-
- NDL書誌ID
- 10777171
-
- Web Site
- https://ndlsearch.ndl.go.jp/books/R000000004-I10777171
- http://link.springer.com/content/pdf/10.1007/s10384-010-0813-1.pdf
- http://link.springer.com/article/10.1007/s10384-010-0813-1/fulltext.html
- http://link.springer.com/content/pdf/10.1007/s10384-010-0813-1
- https://search.jamas.or.jp/link/ui/2011148833
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- IRDB
- NDL
- Crossref
- CiNii Articles
- KAKEN